

NIVS Communication 29 September 2023

From: NIVS NIVS <NIVS@england.nhs.uk>

Sent: 29 September 2023 09:06

Subject: Updated NIVS Release Date

Dear NIVS Superusers

Please disseminate the below communications to all in your organisation who use NIVS

Please be advised the release date for the below has moved to Sunday 1st October 7pm.

NIVS will be unavailable between 19:00 – 22:00 on 1st October 2023 to allow the following changes to be implemented.

Vaccine Decommissioning

NIVS will also be removing the following vaccines from the system. These will no longer be available to Vaccinators on the Add Batch screen and on the vaccination event page.

- Comirnaty Original/Omicron 15micrograms/0.3ml dose (Pfizer)
- Spikevax Omicron 0.1mg/ml dose (Moderna)
- Nuvaxovid 5micrograms/0.5ml dose (Novavax)
- Comirnaty 30micrograms/0.3ml dose (Pfizer)

Please be advised that if you have any of the decommissioned vaccines in the system, these will be automatically marked as depleted in this change.

Addition of new Vaccines

- Comirnaty XBB.1.5 6 months - 4 years /0.2ml(Pfizer Ltd)
- Comirnaty XBB.1.5 Children 5-11 /0.3ml(Pfizer Ltd)
- Comirnaty Omicron XBB.1.5 30micrograms/0.3ml (Pfizer)
- Spikevax XBB.1.5 0.1mg/1ml dose (Moderna)

Revision of programme recommended age in school year 7

Revision for Comirnaty Children 5-11 years to remove children aged 12 in school year 7 from the programme recommended age.

Enabling boosters in the 6 month – 4 years age group

Revision for Comirnaty Children 6 months – 4 years by removing the warning message for booster against this vaccine. The warning message has been removed as a booster dose can now be administered.

Please be advised that the NIVS Team **DOES NOT** send communications via text message. If you ever receive a text message claiming to be from NIVS, **DO NOT** click on any links that are in the text.

Kind regards,

National Immunisation & Vaccination System Support Team

Telephone: **0121 611 0187**

Email: nivs@england.nhs.uk

Web: <http://nivs.ardengemcsu.nhs.uk/home>



This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its content, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail.

This email is intended only for use by the named addressee. It may contain confidential and/or privileged information. If you are not the intended recipient, you should contact us/the sender immediately and should not disclose, use or rely on this email. We do not accept any liability arising from a third party taking action, or refraining from taking action, on the basis of information contained in this email. Thank you